FORUM · Institut für Management GmbH
Vangerowstraße 18
69115 Heidelberg
Phone: +49 6221 500-500
Fax: +49 6221 500-505
Course Patient Access: Early Access, Compassionate Use, Off-label
Patient Access: Early Access,
Compassionate Use,
Off-label Use
2020-06-30 2020-06-30 online

Patient Access: Early Access, Compassionate Use, Off-label Use

Online seminar on HTA, Pricing, Reimbursement & Market Access

This online seminar provides information on early access programmes, HTA requirements, CUP and off-label use in Europe
  • Patient access to orphan drugs and high-price therapies
  • Early access schemes in Europe: Are they reimbursed?
  • Pricing considerations
  • Compassionate use programmes in Europe
  • Compounding, off-label use and hospital exemption

Aims and objectives

This online seminar addresses the various options for fast access to innovative medicines in Europe, the reimbursement options and the mechanisms of compounding and off-label use.
Who should attend
This online seminar is intended for workers in the healthcare industry responsible for market access, healthcare management and, in particular, patient access programmes.
Your speakers
Dr. Marc Christian Bauer
Agios International GmbH, Zug, SWITZERLAND

Christian Hill
MAP BioPharma Limited, Cambridge, GREAT BRITAIN

Dr. Alexander Natz, LL.M.
EUCOPE - European Confederation of Pharmaceutical Entrepreneurs, Brussels, BELGIUM

Pietro Sternini
Atara Biotherapeutics Switzerland GmbH, Zug, SWITZERLAND

Go forward

Pharma Webcast Global RA & PV

Pharma FORUM Webcast International

We would like to invite you to join our live webcasts, where local regulatory affairs and vigilance experts will inform you every two months of the latest news and trends in global marketing authorisation and drug safety.



e-Learning - Click and learn

The FORUM · Institut für Management GmbH provides flexible education and training with high-quality e-Learning programmes for several topics.

You can access top expertise from anywhere.


More on our quality criteria

Quality guaranteed!

IMI (Innovative Medicines Initiative) defined quality criteria for professional training and education. We follow these criteria and, as a signatory, we are an active partner in further developing and optimising the quality standards.

An aggregate evaluation of participants' feedback on all FORUM's healthcare training courses (evaluation period from 01.2019 - 12.2019) produced a result of 1.6 (where 1 is the highest grade and 6 the lowest).